Trinity Biotech PLC (NASDAQ:TRIB – Get Free Report) was the target of a significant increase in short interest in September. As of September 30th, there was short interest totaling 17,870 shares, an increase of 123.3% from the September 15th total of 8,001 shares. Currently, 2.4% of the company’s stock are short sold. Based on an average daily volume of 8,408 shares, the short-interest ratio is presently 2.1 days.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings lowered shares of Trinity Biotech from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, September 4th. One investment analyst has rated the stock with a Sell rating. According to MarketBeat, the stock has a consensus rating of “Sell”.
Read Our Latest Research Report on TRIB
Institutional Inflows and Outflows
Trinity Biotech Stock Performance
NASDAQ:TRIB opened at $6.56 on Tuesday. Trinity Biotech has a 52-week low of $5.01 and a 52-week high of $52.50. The company has a market cap of $5.33 million, a P/E ratio of -0.15 and a beta of 0.73. The stock’s 50-day simple moving average is $8.91 and its 200 day simple moving average is $13.90.
Trinity Biotech Company Profile
Trinity Biotech plc is a biotechnology and medical diagnostics company headquartered in Bray, Ireland. The company develops, manufactures and markets diagnostic products used by clinical laboratories, healthcare professionals and patients.
Its product portfolio includes tests for infectious diseases, autoimmune disorders and diabetes. Trinity Biotech is particularly known for HIV diagnostic products, including rapid and laboratory-based testing solutions, as well as assays and instruments used in clinical testing.
Further Reading
- Five stocks we like better than Trinity Biotech
- Delta’s Guidance Cut Could Spell Trouble for the Airline Industry
- Salesforce Just Got a Rare Double Upgrade—What Changed?
- OpenAI’s Revenue Scare Could Be a Big Opportunity for Investors
- China Still Dominates Rare Earths—These 3 U.S. Companies Could Benefit
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
